The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.
The FDA is adding a new boxed warning to include information that anaphylaxis can occur at any time, from as early as after ...
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...